TAIPEI, Taiwan
PharmaEngine, Inc. (TWO: 4162) announces today the appointment of Alain Herrera, MD, as Senior Advisor. Dr. Herrera will advise us on our clinical strategy and operations, as well as our corporate strategy, licensing and alliance management. PharmaEngine believes that the addition of Dr. Herrera will open a new page of clinical and corporate development for PharmaEngine.
Prior to founding his own consultancy firm, Alain Oncologie Consulting, Dr. Herrera headed the global oncology business at sanofi-aventis for ten years, as Vice President, Global Oncology Business Strategy and Development, and contributed to the worldwide registration of Oxaliplatin（Eloxatin®）and Rasburicase（Fasturtec®/Elitek®）, as well as the gastric and head & neck indications for Docetaxel（Taxotere®）. Other positions include Chairman of Chiron Therapeutics Europe, Managing Director at Pierre Fabre Oncology Laboratories. While at Roger Bellon (Rhône Poulenc), he was involved in evaluating the licensing of irinotecan from Yakult Co., Ltd (Japan) and was responsible for its early clinical development.
“Dr. Herrera who was introduced to us by Prof. Aimery de Gramont (Chief of Oncology Department, Saint-Antoine Hospital, Paris, France) joined our Scientific Advisory Board since 2008, and has been instrumental in advising our clinical and business strategies,” said C. Grace Yeh, Ph.D., President and Chief Executive Officer of PharmaEngine. “I am very pleased to have this opportunity to expand our collaboration with Dr. Herrera, and I believe that his global pharmaceutical industry experience will assist us in fulfilling our goal to be recognized as one of the successful international pharmaceutical companies based in Taiwan.”
Dr. Herrera said, “I am very happy to reinforce my collaboration with PharmaEngine. Since I started working with PharmaEngine more than 4 years ago, I realized that PharmaEngine has a professional team that not only successfully managed the worldwide development of PEP02, but also implemented a unique network of high level investigators from Taiwan, Asia, USA and Europe. I thank very much PharmaEngine for giving me an opportunity to involve such exciting projects to optimally develop innovative compounds in oncology globally.”
About PharmaEngine, Inc. (TWO: 4162)
PharmaEngine, Inc. is a biopharmaceutical company established in Taipei, Taiwan in 2003. PharmaEngine adopts the business model of “no research, development only” and focuses on the development of new drugs for the treatment of cancer and Asian prevalent diseases. The lead project PEP02 (nanoliposomal irinotecan, aka MM-398) which was licensed to Merrimack Pharmaceuticals, Inc., (Cambridge, MA, USA), is in a global phase III study for the treatment of metastatic pancreatic cancer; the second is PEP503 (crystalline hafnium oxide, aka NBTXR3) from Nanobiotix, Inc. (Paris, France); and the third was a collaboration with Guangzhou BeBetter Medicine Technology, Co., Ltd. (Guangzhou, China). For further information, please visit the Company’s website at http://www.pharmaengine.com.
CONTACT
PharmaEngine, Inc.
Peter Wu, (+886)-2-2515-8228, ext. 300
Associate
Director, Corporate Development
Mobile phone No.:
(+886)-2-935-154-559
peter.wu@pharmaengine.com
